Abbott Laboratories ABT
109.29 USD -1.17 (-1.06%)
At closeNov 11, 2026, 6:57 PM EST
109.65 +0.36 +0.33%
After hours · Nov 11, 6:57 PM ET
109.00 Day range 110.33
81.97 52-week range 132.03
- YTD
- -12.77%
- 1 year
- -13.94%
News
zacks.com Is Trending Stock Abbott Laboratories (ABT) a Buy Now? Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
zacks.com Can UltiSynq Lead Boost Abbott's Cardiac Rhythm Management Business? ABT's UltiSynq lead combines conduction system pacing and defibrillation, with strong clinical trial results supporting its potential to expand the company's cardiac rhythm management portfolio.
247wallst.com 3 Legacy Health Care Dividend Stocks That Never Go Out of Style Three health care giants have raised dividends for decades, yet each hides a catch that could shrink or stall a retiree's income. One faces lawsuits, one plans a spinoff, and one raises its payout by…
defenseworld.net Abbott Laboratories $ABT Stock: Allen Investment Management LLC Reduces Stake Allen Investment Management LLC cut its stake in shares of Abbott Laboratories (NYSE: ABT) by 45.6% during the third quarter, according to the company in its most recent Form 13F filing with the SEC.…
defenseworld.net Ashton Thomas Private Wealth LLC Buys 5,216 Shares of Abbott Laboratories $ABT Ashton Thomas Private Wealth LLC boosted its stake in shares of Abbott Laboratories (NYSE: ABT) by 8.2% during the undefined quarter, according to its most recent disclosure with the Securities and…
247wallst.com 3 Medical Device Stocks That Keep Raising Dividends. One Just Hit 55 Years Hospitals reorder syringes, sensors, and implants whether the economy booms or stalls, and three device makers turn that habit into payouts that grow every year.
seekingalpha.com 69 Dividend Champions Ranked By Quality Scores (November 2026) I present 69 Dividend Champions with Dividend Safety scores of 8+ and rank them using my 9F Quality Scores system. Twenty-two featured Dividend Champions are undervalued, while 21 are overvalued.…
seekingalpha.com Dividend Champion, Contender, And Challenger Highlights: Week of November 8 A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.
marketwatch.com These 12 stocks are good bets to beat the 10-year Treasury over the next decade Investment newsletters' favorite Dividend Aristocrat stocks
defenseworld.net 99,391 Shares of Abbott Laboratories $ABT Bought by Associated Banc Corp Associated Banc Corp acquired a new stake in Abbott Laboratories (NYSE: ABT) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange…
defenseworld.net Abbott Laboratories $ABT Stock: Heritage Investors Management Corp Trims Holdings Heritage Investors Management Corp decreased its stake in Abbott Laboratories (NYSE: ABT) by 17.0% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange…
benzinga.com Abbott Touts Favorable Outcomes In Cardiovascular Device Trials Abbott Laboratories (NYSE:ABT) reported positive clinical trial results for two investigational cardiovascular devices at the Transcatheter Cardiovascular Therapeutics conference in San Diego,…
benzinga.com Abbott Touts Favorable Outcomes In Cardiovascular Device Trials Abbott reports positive trial results for its Amulet 360 LAA occluder and SonicForce coronary IVL system at a conference.
benzinga.com Abbott Announces One-Year Results For Its Amulet 360 Left Atrial Appendage Occluder From The VERITAS Study; Data Show Meaningful Closure Rates Of Left Atrial Appendage And A Low Incidence Of Stroke In People With Atrial Fibrillation Not Caused By A Heart Valve Issue The data were presented in a late-breaking session at the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Diego, Calif., on Nov. 1, 2026, and simultaneously published in JACC:…
prnewswire.com Late-breaking one-year data show Abbott's next-generation Amulet 360™ device continues to demonstrate high rates of left atrial appendage closure and low incidence of stroke Late-breaking one-year VERITAS study results were presented at the Transcatheter Cardiovascular Therapeutics conference and simultaneously published in JACC: Cardiovascular Interventions; data show…
247wallst.com 2 Safe S&P 500 Healthcare Dividend Stocks Boomers Can Buy and Hold Forever Arthritis flares, cholesterol checks and cancer treatments arrive on their own schedule, in recessions and booms alike, which is why healthcare draws attention from retirees building an income plan.…- benzinga.com Reported Sunday, Abbott’s TECTONIC Trial Of Investigational SonicForce Coronary IVL System Meets Primary Safety And Effectiveness Endpoints, With 0.3% 30-Day Target Lesion Failure And 97% Procedural Success In 335 Patient SonicForce is an investigational coronary intravascular lithotripsy (IVL) system that uses acoustic pressure waves, similar to those used to break up kidney stones, to crack calcium in coronary…
gurufocus.com Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce⢠Coronary Intravascular Li
prnewswire.com Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System SonicForce is an investigational coronary intravascular lithotripsy (IVL) system that uses acoustic pressure waves, similar to those used to break up kidney stones, to crack calcium in coronary…
fool.com 2 Stocks That Could Quietly Become Big Winners in the Artificial Intelligence (AI) Revolution These aren't top AI stocks, but the technology is helping improve their businesses.- benzinga.com Abbott Initiates CROWN-MV Pivotal Trial Evaluating Safety And Effectiveness Of Its Investigational Cephea Mitral Valve System For Symptomatic Mitral Valve Disease CROWN-MV pivotal trial evaluating the safety and effectiveness of its investigational Cephea™ Mitral Valve System in treating people with symptomatic mitral valve disease who are not candidates for…
prnewswire.com Abbott initiates pivotal trial for Cephea™ device, an innovative treatment for mitral heart valve disease CROWN-MV trial will evaluate the safety and effectiveness of investigational Cephea mitral valve replacement device Abbott's Cephea is designed to provide a new, minimally invasive option for…
seekingalpha.com Best Dividend Aristocrats For November 2026 Dividend Aristocrats underperformed SPY in September but rebounded sharply in October, narrowing the YTD gap. NOBL and the average Aristocrat have YTD returns of 13.13% and 13.35%, trailing SPY's…
finbold.com U.S. politician makes super suspicious Big Tech stock trades Republican Rep. Pete Sessions of Texas has disclosed substantial stock sales involving major technology companies.
benzinga.com This M&T Bank Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday Analysts downgraded M&T Bank, Bank of Hawaii, HubSpot, Abbott and Moderna; Bank of Hawaii cut its target, while HubSpot’s rose.
benzinga.com Abbott Announces Commercial Availability Of Oncodetect Molecular Residual Disease Test Abbott (NYSE: ABT) today announced the commercial availability of its next-generation Oncodetect® MRD test, a personalized, tumor-informed, whole-genome sequencing test designed to provide molecular…
benzinga.com Wells Fargo Maintains Overweight on Abbott Laboratories, Raises Price Target to $120 Wells Fargo analyst Larry Biegelsen maintains Abbott Laboratories (NYSE:ABT) with a Overweight and raises the price target from $119 to $120.
benzinga.com Abbott's New Beta-CORRECT Data At ESMO Congress Demonstrates 30% Enhancement In Sensitivity For Colorectal Cancer Recurrence Within Two Years Of Surgery Abbott (NYSE:ABT) today announced new Beta-CORRECT data presented at the European Society for Medical Oncology (ESMO) Congress showing that the whole-genome sequencing (WGS)-based Oncodetect®…- benzinga.com Citigroup Maintains Buy on Abbott Laboratories, Lowers Price Target to $122 Citigroup analyst Joanne Wuensch maintains Abbott Laboratories (NYSE:ABT) with a Buy and lowers the price target from $125 to $122.
benzinga.com RBC Capital Maintains Outperform on Abbott Laboratories, Lowers Price Target to $125 RBC Capital analyst Kendall Au maintains Abbott Laboratories (NYSE:ABT) with a Outperform and lowers the price target from $130 to $125.
benzinga.com Wells Fargo Maintains Overweight on Abbott Laboratories, Raises Price Target to $119 Wells Fargo analyst Larry Biegelsen maintains Abbott Laboratories (NYSE:ABT) with a Overweight and raises the price target from $112 to $119.- benzinga.com JP Morgan Maintains Overweight on Abbott Laboratories, Lowers Price Target to $118 JP Morgan analyst Robbie Marcus maintains Abbott Laboratories (NYSE:ABT) with a Overweight and lowers the price target from $120 to $118.
- benzinga.com TD Cowen Maintains Buy on Abbott Laboratories, Lowers Price Target to $118 TD Cowen analyst Joshua Jennings maintains Abbott Laboratories (NYSE:ABT) with a Buy and lowers the price target from $135 to $118.
benzinga.com Baird Maintains Outperform on Abbott Laboratories, Raises Price Target to $123 Baird analyst David Rescott maintains Abbott Laboratories (NYSE:ABT) with a Outperform and raises the price target from $121 to $123.- benzinga.com BTIG Maintains Buy on Abbott Laboratories, Lowers Price Target to $125 BTIG analyst Marie Thibault maintains Abbott Laboratories (NYSE:ABT) with a Buy and lowers the price target from $134 to $125.
benzinga.com SpaceX Jumps 10%, Nasdaq 100 Rises as AI Trade Returns: Stock Market Today SpaceX's blowout third quarter and Super Micro's guidance hike revive the AI trade, lifting the Nasdaq 100 as Netflix and AT&T slide on results.
benzinga.com Abbott CEO Rules Out Selling $8.5 Billion Nutrition Business: 'No Interest' Abbott (ABT) to spin off its $8.5B nutrition arm, makers of Ensure & Similac, by end of 2027. Stock dips following Q3 results.
benzinga.com Meta, Tesla On Deck Wednesday As AI Spending, Auto Demand Face Test Meta Platforms and Tesla headline Wednesday’s reports, with investors focused on whether AI investment can keep driving growth while Tesla’s core auto business weakens. Philip Morris International,…
benzinga.com Abbott Laboratories Q3 2026 Earnings Call Transcript Abbott Laboratories (NYSE:ABT) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…- benzinga.com Abbott Laboratories Narrows FY2026 Adj EPS Guidance from $5.45-$5.60 to $5.50-$5.55 vs $5.52 Est Abbott Laboratories (NYSE:ABT) narrows FY2026 Adj EPS guidance from $5.45-$5.60 to $5.50-$5.55 vs $5.52 analyst estimate..
benzinga.com Abbott Laboratories Q3 Adj. EPS $1.42, Inline, Sales $13.013B Beat $12.998B Estimate Abbott Laboratories (NYSE:ABT) reported quarterly earnings of $1.42 per share which met the analyst consensus estimate. This is a 9.23 percent increase over earnings of $1.30 per share from the same…- benzinga.com Abbott To Spin Off Nutrition Business Into Independent Public Company With $8.5B In Annual Sales; Separation Expected To Be Completed By 2027 End Separation will unlock potential of both companies to pursue distinct growth and value-creation strategiesThe new Nutrition company will be a global leader in the rapidly growing healthy nutrition…
benzinga.com How To Earn $500 A Month From Abbott Stock Ahead Of Q3 Earnings Abbott expects Q3 EPS of $1.41 and $12.99B revenue. Its 2.42% dividend requires about $247,767 invested to generate $500 monthly.
benzinga.com Top Wall Street Forecasters Revamp Abbott Expectations Ahead Of Q3 Earnings Abbott reports Q3 earnings Oct. 21; analysts expect $1.41 EPS and $12.99B revenue. FDA approved CardioMEMS updates.- benzinga.com TD Cowen Reiterates Buy on Abbott Laboratories, Maintains $135 Price Target TD Cowen analyst Joshua Jennings reiterates Abbott Laboratories (NYSE:ABT) with a Buy and maintains $135 price target.
benzinga.com This Generac Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday Analysts initiated coverage: Overweight GNRC ($303), Buy ENTG ($200) and VYLR ($87), Neutral SPOT ($540).- benzinga.com Eli Lilly To Rally Over 21%? Here Are 10 Top Analyst Forecasts For Thursday Analysts raised targets for Everpure, Eli Lilly and Delek US, while cutting targets for Constellation, Tyler, ArriVent and Netflix.
benzinga.com This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday Analysts initiated coverage: Neutral on Honeywell Aerospace; Outperform on M&T Bank and SailPoint; Buy on Ambiq Micro; Overweight on Abbott.
benzinga.com Micron To Rally Around 187%? Here Are 10 Top Analyst Forecasts For Wednesday Wall Street analysts revised targets: upgrades for NetApp and Humana; downgrades for PJT Partners; mixed target changes for Redwood, Marvell, Yum and S&P- benzinga.com Barclays Initiates Coverage On Abbott Laboratories with Overweight Rating, Announces Price Target of $120 Barclays analyst Matt Miksic initiates coverage on Abbott Laboratories (NYSE:ABT) with a Overweight rating and announces Price Target of $120.